Prostanoid EP3 and TP receptors-mediated inhibition of noradrenaline release from the isolated rat stomach

European Journal of Pharmacology

Volumn 459, Issue 2-3, 2003, Pages 187-193

  Yokotani, Kunihiko ^a   Nakamura, Kumiko ^a   Okada, Shoshiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

EP3 receptor; Noradrenaline release; Pertussis toxin; Stomach, rat; TP receptor

Indexed keywords

11,15 O DIMETHYL PROSTAGLANDIN E2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 16 (3 METHOXYMETHYL)PHENYL OMEGA TETRANOR 3,7 DITHIAPROSTAGLANDIN E1; 2,5 ETHANO 6 OXO 17,20 DIMETHYL PROSTAGLANDIN E1; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [3 [3 HYDROXY 4 (4 IODOPHENOXY) 1 BUTENYL] 7 OXABICYCLO[2,2,1]HEPT 2 YL][1ALPHA,2ALPHA(Z),3BETA,4ALPHA] 5 HEPTANOIC ACID; 9 DEOXY 9BETA 16 HYDROXY 17,17 TRIMETHYLENE 19,20 DIDEHYDROPROSTAGLANDIN F2; HEPTANOIC ACID DERIVATIVE; NORADRENALIN; ONO AE 248; ONO AE1 259 01; ONO AE1 329; ONO DI 004; PERTUSSIS TOXIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN EP3 RECEPTOR; THROMBOXANE RECEPTOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; HORMONE RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH; SYMPATHETIC NERVE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; NERVE CELL INHIBITION; PHYSIOLOGY; SECRETION; WISTAR RAT;

ANIMALS; ELECTRIC STIMULATION; MALE; NEURAL INHIBITION; NOREPINEPHRINE; RATS; RATS, WISTAR; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, THROMBOXANE; STOMACH;

EID: 0037449473     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02857-1     Document Type: Article

References (37)

1. 2 to different transduction pathways in arginine vasopressin- and glucagon-sensitive segments of the rat renal tubule. Br. J. Pharmacol. 126:1999;1041-1049.
2. Anton A.H., Sayre D.F. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther. 138:1962;360-375.
3. Bokoch G.M., Katada T., Northup J.K., Hewlett E.L., Gilman A.G. Identification of the predominant substrate for ADP-ribosylation by islet activating protein. J. Biol. Chem. 258:1983;2072-2075.
4. 2 inhibits calcium current in two sub-populations of acutely isolated mouse trigeminal sensory neurons. J. Physiol. 539:2002;433-444.
5. Cao J., Shayibuzhati M., Tajima T., Kitazawa T., Taneike T. In vitro pharmacological characterization of the prostanoid receptor population in the non-pregnant porcine myometrium. Eur. J. Pharmacol. 442:2002;115-123.
6. 2 on some isolated smooth muscle preparations. Br. J. Pharmacol. 73:1981;773-778.
7. Coleman R.A., Smith W.L., Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
8. 2 on noradrenaline release in the mouse brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:1995;46-52.
9. Fuder H., Muscholl E. Heteroreceptor-mediated modulation of noradrenaline and acetylcholine release from peripheral nerves. Rev. Physiol. Biochem. Pharmacol. 126:1995;265-412.
10. Güllner H.G. The interactions of prostaglandins with the sympathetic nervous system. J. Auton. Nerv. Syst. 8:1983;1-12.
11. Hedqvist P. Basic mechanisms of prostaglandin action on autonomic neurotransmission. Annu. Rev. Pharmacol. Toxicol. 17:1977;259-279.
12. Holmquist F., Hedlund H., Andersson K.E. Pre- and postjunctional effects of some prostanoids in human isolated vas deferens. Am. J. Physiol. 260:1991;R792-R797.
13. Hsu K.S., Huang C.C., Kan W.M., Gean P.W. TXA2 agonists inhibit high-voltage-activated calcium channels in rat hippocampal CA1 neurons. Am. J. Physiol. 271:1996;C1269-C1277.
14. 2 of noradrenaline release from sympathetic neurones in rabbit aorta. Pharmacol. Toxicol. 80:1997;18-23.
15. Jensen T.J., Nedergaard O.A. Modulation of norepinephrine release from sympathetic neurons of the rabbit aorta by prejunctional prostanoid receptors. J. Pharmacol. Exp. Ther. 291:1999;7-11.
16. Katada T., Ui M. Islet-activating protein. A modifier of receptor-mediated regulation of rat islet adenylate cyclase. J. Biol. Chem. 256:1981;8310-8317.
17. Kennedy I., Coleman R.A., Humphrey P.P., Levy G.P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 24:1982;667-689.
18. Malik K.U., Sehic E. Prostaglandins and the release of the adrenergic transmitter. Ann. N. Y. Acad. Sci. 604:1990;222-236.
19. 3 subtype. Br. J. Pharmacol. 102:1991;573-576.
20. 3 receptor knockout mice. Br. J. Pharmacol. 133:2001;438-444.
21. 3-subtype. Br. J. Pharmacol. 107:1992;352-355.
22. 3- and DP-receptors. Br. J. Pharmacol. 111:1994;733-738.
23. 3- and DP-receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;440-444.
24. Morinelli T.A., Mais D.E., Oatis J.E., Mayeux P.R., Okwu A.K., Masuda A., Knapp D.R., Halushka P.V. I-BOP, the most potent radiolabelled agonist for the TXA2/PGH2 receptor. Adv. Prostaglandin Thromboxane Leukotriene Res. 20:1990;102-109.
25. 2/prostaglandin H2 receptors. J. Pharmacol. Exp. Ther. 262:1992;632-637.
26. 2 on isolated dog mesenteric arteries. Prostaglandins. 27:1984;407-419.
27. 2 mimetic, inhibits the release of endogenous noradrenaline from the rat hippocampus in vitro. Jpn. J. Pharmacol. 82:2000;226-231.
28. 2 and centrally activates adrenomedullary outflow in rats. Neuroscience. 96:2000;585-590.
29. Racké K., Berrino L., Möhlig A., Jäger R., Griepenkerl I., Bräutigam M., Reimann A. Modulation of noradrenaline release in rat isolated stomach by prostanoids, but not by histaminergic mechanisms. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;631-639.
30. 3 receptors on the noradrenergic terminals in the mouse brain. Neuroscience. 79:1997;247-254.
31. Schwaner I., Offermanns S., Spicher K., Seifert R., Schultz G. Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line. HEL. Biochim. Biophys. Acta. 1265:1995;8-14.
32. Starke K., Gothert M., Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 69:1989;864-989.
33. 4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 141:2000;1554-1559.
34. Trachte G.J., Stein E.A. Thromboxane receptor agonists enhance adrenergic neurotransmission in rabbit isolated mesenteric arteries. J. Pharmacol. Exp. Ther. 249:1989;216-220.
35. Yokotani K., Osumi Y. Cholinergic M2 muscarinic receptor-mediated inhibition of endogenous noradrenaline release from the isolated vascularly perfused rat stomach. J. Pharmacol. Exp. Ther. 264:1993;54-60.
36. Yokotani K., Okuma Y., Osumi Y. Release of endogenous noradrenaline from the vascularly perfused rat stomach in vitro: modulation by pre- and postsynaptic adrenoceptors. J. Pharmacol. Exp. Ther. 260:1992;728-733.
37. 2+ channels in the release of endogenous noradrenaline from the isolated vascularly perfused rat stomach. Jpn. J. Pharmacol. 78:1998;75-77.